Key terms
About ALLO
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ALLO news
Apr 26
8:32am ET
Allogene awarded $15M grant from CIRM to support ALLO-316 development
Apr 15
8:42am ET
IO Biotech appoints Shamsaei as SVP, Commercial Development
Mar 20
4:55am ET
Allogene Therapeutics management to meet with Truist
Mar 19
10:05pm ET
Stifel Nicolaus Sticks to Their Hold Rating for Allogene Therapeutics (ALLO)
Mar 19
8:11am ET
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)
Mar 19
6:27am ET
Allogene Therapeutics: A Buy Rating on Strong Financials and Promising Clinical Prospects
Mar 19
4:55am ET
Allogene Therapeutics management to meet with Truist
Mar 19
1:46am ET
Allogene Therapeutics Poised for Growth: A Strong Buy Rating Amidst Innovative Trials and Strategic Advancements
Mar 18
4:22pm ET
Allogene Therapeutics management to meet with Truist
Mar 16
2:01am ET
Allogene Therapeutics’ Stability Threatened by Banking Sector Turmoil
Mar 15
12:03pm ET
JPMorgan biotech/pharma analysts hold an analyst/industry conference call
Mar 14
5:22pm ET
Allogene Therapeutics files $500M mixed securities shelf
Mar 14
4:29pm ET
Allogene Therapeutics sees $190M reduction in cash in 2024
Mar 14
4:28pm ET
Allogene Therapeutics reports Q4 EPS (51c), consensus (45c)
Mar 12
12:50pm ET
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Pliant Therapeutics (PLRX)
Mar 12
8:41am ET
Allogene, Arbor enter global gene editing license agreement
Mar 07
4:55am ET
Allogene Therapeutics management to meet with Truist
Mar 06
5:55am ET
Allogene Therapeutics management to meet with Truist
Mar 04
10:24am ET
Allogene Therapeutics management to meet with Truist
Feb 16
8:35am ET
Allogene Therapeutics to restate previously filed financial statements
Feb 15
1:23am ET
Allogene Therapeutics: A Strong Buy on Promising ALPHA3 Study and Potential Clinical Success
No recent press releases are available for ALLO
ALLO Financials
Key terms
Ad Feedback
ALLO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ALLO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range